Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 44 CMW2.3 | DOI: 10.1530/endoabs.44.CMW2.3

Sheffield Teaching Hospitals, NHS Foundation Trust, Sheffield, UK.


The management of congenital adrenal hyperplasia is challenging. Patients suffer from multiple morbidities related to excess androgens or glucocorticoid over-replacement. Multiple studies in Europe and the US have shown a high rate of metabolic complications in patients suffering from CAH including obesity, hypercholesterolaemia, insulin resistance, high blood pressure and low bone mineral density. Some studies have shown that patients with CAH have a poor quality of life and impaired fertility and the condition has also been associated with an excess mortality due to adrenal crises. It has been suggested that non-physiological glucocorticoid replacement in these patients could be one of the prime factors resulting in these complications. Different groups are developing novel strategies for treatment to mirror the physiological cortisol rhythm and provide more effective treatment resulting in less adverse effects; these include oral formulations of modified release hydrocortisone or subcutaneous hydrocortisone infusions. Other upcoming treatments added to a regime including glucocorticoids and mineralocorticoids, acting to directly suppress androgens, include CRF1 receptor antagonists and CYP17A1 inhibitors. Endocrinologists all over the world continue to play a central role in the management of patients with CAH and together with other members of the multidisciplinary team it is our duty to persist with improving health outcomes.

Volume 44

Society for Endocrinology BES 2016

Brighton, UK
07 Nov 2016 - 09 Nov 2016

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts